Wildcat Capital Management’s Entera Bio ENTX Stock Holding History

Wildcat Capital Management’s Portfolio ENTX Stock Details ENTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-130,926	Closed	-$269K	–	30
2020 Q2	$269K	Sell	130,926 -48,600	-27%	-$99.2K	0.09%	30
2020 Q1	$369K	Hold	179,526	–	–	0.17%	19
2019 Q4	$384K	Sell	179,526 -13,664	-7%	-$31.3K	0.11%	26
2019 Q3	$481K	Sell	193,190 -10,000	-5%	-$28.5K	0.2%	24
2019 Q2	$697K	Hold	203,190	–	–	0.3%	24
2019 Q1	$853K	Hold	203,190	–	–	0.5%	17
2018 Q4	$620K	Buy	+203,190	New	+$1.01M	0.41%	17

Other funds holding ENTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wildcat Capital Management's ENTX Position: Q3 2020 in Review

Wildcat Capital Management sold out of Entera Bio (ENTX) in Q3 2020, closing a stake of 130,926 shares — an estimated $269K sold.

Wildcat Capital Management first reported a position in ENTX in Q4 2018 and held it in 7 quarters. The position peaked at $853K in Q1 2019. 5 funds tracked by Wall St. Rank hold ENTX as of Q3 2020.

Wildcat Capital Management reported no remaining Entera Bio position as of Q3 2020 after selling out during the quarter.
Wildcat Capital Management sold 130,926 Entera Bio shares in Q3 2020, an estimated $269K.
Wildcat Capital Management first reported a position in Entera Bio in Q4 2018 and held it in 7 quarters.
Wildcat Capital Management's Entera Bio position peaked at $853K in Q1 2019.
5 funds tracked by Wall St. Rank held Entera Bio as of Q3 2020.

Based on Wildcat Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.